These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22819097)

  • 1. Changes in exercise capacity and cardiac performance in a series of patients with Eisenmenger's syndrome transitioned from selective to dual endothelin receptor antagonist.
    Kopeć G; Tyrka A; Miszalski-Jamka T; Mikołajczyk T; Waligóra M; Guzik T; Podolec P
    Heart Lung Circ; 2012 Nov; 21(11):671-8. PubMed ID: 22819097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term results of treatment with bosentan in adult Eisenmenger's syndrome patients with Down's syndrome related to congenital heart disease.
    Crepaz R; Romeo C; Montanaro D; De Santis S
    BMC Cardiovasc Disord; 2013 Sep; 13():74. PubMed ID: 24047157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of patients with Eisenmenger's syndrome with Bosentan.
    Brun H; Thaulow E; Fredriksen PM; Holmstrom H
    Cardiol Young; 2007 Jun; 17(3):288-94. PubMed ID: 17451611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelin receptor antagonists improve exercise tolerance and oxygen saturations in patients with Eisenmenger syndrome and congenital heart defects.
    Mehta PK; Simpson L; Lee EK; Lyle TA; McConnell ME; Book WM
    Tex Heart Inst J; 2008; 35(3):256-61. PubMed ID: 18941642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension.
    Fox B; Langleben D; Hirsch AM; Schlesinger RD; Eisenberg MJ; Joyal D; Blenkhorn F; Lesenko L
    Can J Cardiol; 2013 Jun; 29(6):672-7. PubMed ID: 22819360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease.
    Diller GP; Dimopoulos K; Kaya MG; Harries C; Uebing A; Li W; Koltsida E; Gibbs JS; Gatzoulis MA
    Heart; 2007 Aug; 93(8):974-6. PubMed ID: 17639112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension.
    Safdar Z
    Vasc Health Risk Manag; 2011; 7():119-24. PubMed ID: 21468170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of bosentan in adults with simple and complex Eisenmenger's syndrome.
    Williams R; Houser L; Miner P; Aboulhosn J
    Congenit Heart Dis; 2012; 7(1):12-5. PubMed ID: 22188797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Greater functional ETB receptor antagonism with bosentan than sitaxsentan in healthy men.
    MacIntyre IM; Dhaun N; Lilitkarntakul P; Melville V; Goddard J; Webb DJ
    Hypertension; 2010 Jun; 55(6):1406-11. PubMed ID: 20404221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The effect of an endothelin receptor antagonist in Eisenmenger syndrome: a single-center experience of 11 patients].
    Poindron D; Godart F; Duhamel A; Richard A; Francart C; Brevière GM; Rey C
    Arch Mal Coeur Vaiss; 2006 May; 99(5):457-62. PubMed ID: 16802735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan.
    Benza RL; Mehta S; Keogh A; Lawrence EC; Oudiz RJ; Barst RJ
    J Heart Lung Transplant; 2007 Jan; 26(1):63-9. PubMed ID: 17234519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial experience with bosentan therapy in patients with the Eisenmenger syndrome.
    Christensen DD; McConnell ME; Book WM; Mahle WT
    Am J Cardiol; 2004 Jul; 94(2):261-3. PubMed ID: 15246919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome.
    Galie N; Manes A; Palazzini M; Negro L; Marinelli A; Gambetti S; Mariucci E; Donti A; Branzi A; Picchio FM
    Drugs; 2008; 68(8):1049-66. PubMed ID: 18484798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease.
    Kotlyar E; Sy R; Keogh AM; Kermeen F; Macdonald PS; Hayward CS; McNeil KD; Celermajer DS
    Cardiol Young; 2006 Jun; 16(3):268-74. PubMed ID: 16725066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term bosentan treatment of complex congenital heart disease and Eisenmenger's syndrome.
    Díaz-Caraballo E; González-García AE; Reñones M; Sánchez-Recalde A; García-Río F; Oliver-Ruiz JM
    Rev Esp Cardiol; 2009 Sep; 62(9):1046-9. PubMed ID: 19712626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension.
    Beghetti M; Galiè N
    J Am Coll Cardiol; 2009 Mar; 53(9):733-40. PubMed ID: 19245962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of bosentan on plasma endothelin-1 concentration in patients with pulmonary arterial hypertension.
    Hiramoto Y; Shioyama W; Kuroda T; Masaki M; Sugiyama S; Okamoto K; Hirota H; Fujio Y; Hori M; Yamauchi-Takihara K
    Circ J; 2007 Mar; 71(3):367-9. PubMed ID: 17322637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study.
    Galiè N; Beghetti M; Gatzoulis MA; Granton J; Berger RM; Lauer A; Chiossi E; Landzberg M;
    Circulation; 2006 Jul; 114(1):48-54. PubMed ID: 16801459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease.
    Apostolopoulou SC; Manginas A; Cokkinos DV; Rammos S
    Heart; 2005 Nov; 91(11):1447-52. PubMed ID: 15761050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study.
    Gatzoulis MA; Beghetti M; Galiè N; Granton J; Berger RM; Lauer A; Chiossi E; Landzberg M;
    Int J Cardiol; 2008 Jun; 127(1):27-32. PubMed ID: 17658633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.